Lenalidomide in Diffuse Large B-Cell Lymphoma

Table 3

Response to lenalidomide in patients with diffuse large B-cell lymphoma in first-line treatment.

Name of the protocol	R2-CHOP [56]	LR-CHOP21 [57]	R2-CHOP [58]
Year of publication	2011	2010	2011
Type of study	Monocentric	Multicentric-IIL	Multicentric
Phase	Phase I	Phase I-II	Phase I-II
Treatment	Lenalidomide and R-CHOP21	Lenalidomide and R-CHOP21	LenalidomideandR-CHOP21
Dose of lenalidomide:	15 to 25 mg/d, D1–10	5 to 20 mg/d, D1–14	5 to 25 mg/d, D1–14
	every 21 days	every 21 days	every 21 days
No. of cycles	6	6	6
No. of patients; with DLBCL	24	21	27
Recommended dose; in function of DLT	25 mg	15 mg	25 mg
Toxicity
Hematologic	Grade III-IV	Grade III-IV	Grade III-IV
Anemia	21%	4%	—
Neutropenia	88%	28%	59%
Thrombocytopenia	29%	10%	30%
	Grade III	Grade III	Grade I-II	Grade III
Peripheral neurotoxicity	8%	14%	48%	0%
Vascular thrombosis	8%		7%
Response
ORR 𝑛, (%)	22 (87.5)	16 (72)	27 (100)
CR 𝑛, (%)	18 (77)	15 (71)	20 (74)
PR 𝑛, (%)		1 (5)	7 (26)
Stable disease 𝑛, (%)			—
Progression 𝑛, (%)	5 (21)	5 (16)	—

R-CHOP: rituximab 375 mg/m² D1, cyclophosphamide 750 mg/m² D1, doxorubicin 50 mg/m² D1, vincristine 1.4 mg/m² D1 (capped at 2.0 mg) prednisone 50 mg/m² D1–5.
DTL: dose limiting toxicity.